PharmaTimesJanssen acquires BeneVir Biopharm to advance immunotherapy …PharmaTimesBeneVir engineers oncolytic viruses tailored to infect and destroy cancer cells – News – PharmaTimes.and more »… Continue reading
labiotech (press release) (blog) |
World’s First Gene Therapy Developer Hopes to Raise $128M for Hemophilia and Huntington’s
labiotech (press release) (blog) uniQure hopes to raise a substantial public offering on the NASDAQ early next week. If successful, this could help the Dutch gene therapy pioneer recover after hitting a rough patch last year. Amsterdam-based uniQure plans to raise an ambitious $128M … |
labiotech (press release) (blog) |
World’s First Gene Therapy Developer Hopes to Raise $128M for Hemophilia and Huntington’s
labiotech (press release) (blog) uniQure hopes to raise a substantial public offering on the NASDAQ early next week. If successful, this could help the Dutch gene therapy pioneer recover after hitting a rough patch last year. Amsterdam-based uniQure plans to raise an ambitious $128M … |
The Sun Daily |
Scientists build ‘synthetic embryos’
BBC News Dutch scientists have built “synthetic” embryos in their laboratory using mouse cells other than sperm and eggs. The stem cell breakthrough, described in Nature journal, is not for cloning people or animals, but about understanding why many pregnancies … Breakthough: Lab-made mouse proto-embryoNew Straits Times Online No sperm or egg required: Mouse proto-embryo made in the labGMA News |
|
More Progress on LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
PR Newswire (press release) The rapidly emerging immunotherapy approach, known as CAR (chimeric antigen receptor) T–cell immunotherapy, uses genetic engineering to reprogram the patient’s own immune T cells to find and kill cancer cells. These engineered T cells persist in the … |